Pharmaco-economics of levosimendan in cardiology: A European perspective.

INTRODUCTION: Heart failure places a significant economic burden on health care. Acute heart failure requires hospitalization and often frequent re-hospitalization in expensive wards where vasoactive rescue therapy is often added on top of standard medications. In these lean times, there is a growin...

Descripción completa

Detalles Bibliográficos
Autores: Nieminen, Markku Sakari, Buerke, Michael, Parissis, John, Ben-Gal, Tuvia, Pollesello, Piero, Kivikko, Matti, Karavidas, Apostolos, Severino, Paolo, Comín Colet, Josep, Wikström, Gerhard, Fedele, Frencesco
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2015
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/25004
Acceso en línea:http://hdl.handle.net/10230/25004
http://dx.doi.org/10.1016/j.ijcard.2015.07.049
Access Level:acceso embargado
Palabra clave:Infart de miocardi
id ES_3d8bfe6c7c27a75cd5e91d9c4e296099
oai_identifier_str oai:repositori.upf.edu:10230/25004
network_acronym_str ES
network_name_str España
repository_id_str
spelling Pharmaco-economics of levosimendan in cardiology: A European perspective.Nieminen, Markku SakariBuerke, MichaelParissis, JohnBen-Gal, TuviaPollesello, PieroKivikko, MattiKaravidas, ApostolosSeverino, PaoloComín Colet, JosepWikström, GerhardFedele, FrencescoInfart de miocardiINTRODUCTION: Heart failure places a significant economic burden on health care. Acute heart failure requires hospitalization and often frequent re-hospitalization in expensive wards where vasoactive rescue therapy is often added on top of standard medications. In these lean times, there is a growing need for cost-effective therapeutic options that supply superior support and in addition shorten the length of stay in hospital and reduce re-hospitalization rates. The inodilator levosimendan represents the latest addition to the vasoactive treatments of acute heart failure patients, and it appears to meet these expectations. Our aim was to answer the question whether the treatment efficacy of levosimendan - when selected as therapy for patients hospitalized for acute heart failure - brings savings to hospitals in various European countries representing different economies. METHODS AND RESULTS: We took a conservative approach and selected some a fortiori arguments to simplify the calculations. We selected seven European countries to represent different economies: Italy, Spain, Greece, Germany, Sweden, Finland and Israel. Data on the costs of medications and on the cost per day were collected and fed in a simple algorithm to detect savings. These saving varied from country to country, from a minimum of €0.50 in Germany to a maximum of €354.64 in Sweden. CONCLUSIONS: The use of levosimendan as a therapy for patients hospitalized for acute heart failure provides a net saving to hospitals driven by a reduction in the length of hospital stay. This finding is true in each of the countries considered in this study.Elsevier201520152015info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/25004http://dx.doi.org/10.1016/j.ijcard.2015.07.049reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésInternational Journal of Cardiology. 2015 Nov 15;199:337-410167-5273/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/embargoedAccessoai:repositori.upf.edu:10230/250042026-06-12T07:21:37Z
dc.title.none.fl_str_mv Pharmaco-economics of levosimendan in cardiology: A European perspective.
title Pharmaco-economics of levosimendan in cardiology: A European perspective.
spellingShingle Pharmaco-economics of levosimendan in cardiology: A European perspective.
Nieminen, Markku Sakari
Infart de miocardi
title_short Pharmaco-economics of levosimendan in cardiology: A European perspective.
title_full Pharmaco-economics of levosimendan in cardiology: A European perspective.
title_fullStr Pharmaco-economics of levosimendan in cardiology: A European perspective.
title_full_unstemmed Pharmaco-economics of levosimendan in cardiology: A European perspective.
title_sort Pharmaco-economics of levosimendan in cardiology: A European perspective.
dc.creator.none.fl_str_mv Nieminen, Markku Sakari
Buerke, Michael
Parissis, John
Ben-Gal, Tuvia
Pollesello, Piero
Kivikko, Matti
Karavidas, Apostolos
Severino, Paolo
Comín Colet, Josep
Wikström, Gerhard
Fedele, Frencesco
author Nieminen, Markku Sakari
author_facet Nieminen, Markku Sakari
Buerke, Michael
Parissis, John
Ben-Gal, Tuvia
Pollesello, Piero
Kivikko, Matti
Karavidas, Apostolos
Severino, Paolo
Comín Colet, Josep
Wikström, Gerhard
Fedele, Frencesco
author_role author
author2 Buerke, Michael
Parissis, John
Ben-Gal, Tuvia
Pollesello, Piero
Kivikko, Matti
Karavidas, Apostolos
Severino, Paolo
Comín Colet, Josep
Wikström, Gerhard
Fedele, Frencesco
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Infart de miocardi
topic Infart de miocardi
description INTRODUCTION: Heart failure places a significant economic burden on health care. Acute heart failure requires hospitalization and often frequent re-hospitalization in expensive wards where vasoactive rescue therapy is often added on top of standard medications. In these lean times, there is a growing need for cost-effective therapeutic options that supply superior support and in addition shorten the length of stay in hospital and reduce re-hospitalization rates. The inodilator levosimendan represents the latest addition to the vasoactive treatments of acute heart failure patients, and it appears to meet these expectations. Our aim was to answer the question whether the treatment efficacy of levosimendan - when selected as therapy for patients hospitalized for acute heart failure - brings savings to hospitals in various European countries representing different economies. METHODS AND RESULTS: We took a conservative approach and selected some a fortiori arguments to simplify the calculations. We selected seven European countries to represent different economies: Italy, Spain, Greece, Germany, Sweden, Finland and Israel. Data on the costs of medications and on the cost per day were collected and fed in a simple algorithm to detect savings. These saving varied from country to country, from a minimum of €0.50 in Germany to a maximum of €354.64 in Sweden. CONCLUSIONS: The use of levosimendan as a therapy for patients hospitalized for acute heart failure provides a net saving to hospitals driven by a reduction in the length of hospital stay. This finding is true in each of the countries considered in this study.
publishDate 2015
dc.date.none.fl_str_mv 2015
2015
2015
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/25004
http://dx.doi.org/10.1016/j.ijcard.2015.07.049
url http://hdl.handle.net/10230/25004
http://dx.doi.org/10.1016/j.ijcard.2015.07.049
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv International Journal of Cardiology. 2015 Nov 15;199:337-41
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/embargoedAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv embargoedAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406453804040192
score 15.81155

Similares en LA Referencia